Immunotherapy for pancreatic cancer (Q38722325)

5 September 2017

1 reference

title

Immunotherapy for pancreatic cancer (English)

1 reference

5 September 2017

1 reference

1 reference

Elias Kotteas

1

1 reference

PubMed ID

26843405

5 September 2017

Muhammad Wasif Saif

series ordinal

2

1 reference

PubMed ID

26843405

5 September 2017

Konstantinos Syrigos

series ordinal

3

1 reference

5 September 2017

3 February 2016

1 reference

Journal of Cancer Research and Clinical Oncology

5 September 2017

1 reference

5 September 2017

142

1 reference

5 September 2017

8

1 reference

5 September 2017

1795-1805

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-016-2119-2

5 September 2017

0 references

cites work

Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

The role of the FOLFIRINOX regimen for advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Mucins: a biologically relevant glycan barrier in mucosal protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Current status of interleukin-10 and regulatory T-cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Immunotherapy updates in pancreatic cancer: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Clinical implications of dysregulated cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Principles of adoptive T cell cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Mutant KRAS is a druggable target for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Cancer and the Immune System: Basic Concepts and Targets for Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Guidelines for the safe administration of high-dose interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

21 January 2018

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Current advances in immunotherapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Toxicities of Immunotherapy for the Practitioner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2119-2

Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer

21 January 2018

1 reference

12 December 2020

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

1 reference

12 December 2020

Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors.

1 reference

12 December 2020

Expression of the co-signaling molecules CD40-CD40L and their growth inhibitory effect on pancreatic cancer in vitro

1 reference

12 December 2020

A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients.

1 reference

12 December 2020

Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets

1 reference

12 December 2020

The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion

1 reference

12 December 2020

A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer

1 reference

12 December 2020

A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.

1 reference

12 December 2020

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies

1 reference

12 December 2020

Advances in the assessment and control of the effector functions of therapeutic antibodies

1 reference

12 December 2020

Clinical Development of Immune Checkpoint Inhibitors

1 reference

12 December 2020

10.1007/S00432-016-2119-2

Identifiers

DOI

1 reference

5 September 2017

1 reference

PubMed ID

26843405